Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Smith & Nephew Snats ( (SNN) ) has issued an announcement.
On April 30, 2025, Smith & Nephew plc held its Annual General Meeting (AGM) where all proposed resolutions were passed by shareholders. Significant resolutions included the approval of the Directors’ Remuneration Report, the declaration of a final dividend, and the re-election of several directors. The company also renewed authorizations for share allotment and market purchases, indicating a stable governance structure and strategic financial planning. The withdrawal of Resolution 15 was noted due to Bob White’s resignation from the Board on the same day.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
Smith & Nephew Snats receives a solid overall score of 77.0, driven by strong financial performance and positive earnings call sentiment. The company’s impressive revenue and profit growth, coupled with innovation-driven strategies, contribute to a favorable outlook. However, high valuation ratios and technical analysis indicators suggest caution. Challenges in the China market and input cost pressures in Orthopedics remain key risks.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a global medical technology company headquartered in Watford, England. The company specializes in advanced wound management, orthopedics, and sports medicine, focusing on providing innovative solutions to improve patient outcomes.
YTD Price Performance: 10.79%
Average Trading Volume: 854,802
Technical Sentiment Signal: Hold
Current Market Cap: $11.72B
For a thorough assessment of SNN stock, go to TipRanks’ Stock Analysis page.